These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3065506)

  • 1. Rapid development of tolerance to the antihypertensive effect of nisoldipine.
    Ramsay LE; Waller PC
    J Hum Hypertens; 1988 Mar; 1(4):277-80. PubMed ID: 3065506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of arterial hypertension in the aged with a calcium antagonist: nicardipine].
    Forette F; Bellet M; Henry JF; Hervy MP; Poyard-Salmeron C; Bouchacourt P
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1242-6. PubMed ID: 6441544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of nisoldipine and atenolol in the treatment of essential hypertension.
    Takahashi H; Fukuyama M; Yoneda S; Okabayashi H; Yoshimura M
    Arzneimittelforschung; 1989 Mar; 39(3):379-82. PubMed ID: 2667523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nisoldipine in the treatment of essential hypertension. Efficacy and tolerance].
    Deeg P; Weiss KH; Schmitz H
    Dtsch Med Wochenschr; 1987 Mar; 112(11):429-33. PubMed ID: 3545744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. A placebo-controlled, double-blind parallel-group trial.
    Harder S; Rietbrock S; Thürmann P
    Arzneimittelforschung; 1994 Feb; 44(2):133-6. PubMed ID: 8147945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension.
    Svetkey LP; Weinberger MH; Gavras H; Gavras I; Brown TS; Deterding J; Klotman PE
    J Clin Hypertens; 1987 Dec; 3(4):579-88. PubMed ID: 3330988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
    Leonetti G;
    Curr Med Res Opin; 2005 Jun; 21(6):951-8. PubMed ID: 15969895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amlodipine and captopril in moderate-severe essential hypertension.
    Maclean D; Mitchell ET; Wilcox RG; Walker P; Tyler HM
    J Hum Hypertens; 1988 Aug; 2(2):127-32. PubMed ID: 2977406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypotensive properties of nisoldipine. Comparative study in essential, renal and renovascular hypertension].
    Wambach G; Breuer G; Kaufmann W
    Arzneimittelforschung; 1984; 34(5):620-3. PubMed ID: 6540581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muzolimine and nitrendipine in the treatment of arterial hypertension.
    de Divitiis O; Di Somma S; Petitto M; Galderisi M; Iacono C; Fazio S
    Z Kardiol; 1985; 74 Suppl 2():60-5. PubMed ID: 3159163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, controlled, multicenter, randomized study comparing the antihypertensive effectiveness and tolerance of a daily dose of two nifedipine formulations: nifedipine microgranules versus nifedipine osmotic pump.
    de Roa ER; Botero R; Octavio JA; Berrizbeitia ML; Mayorca E; Castro P; Miranda R; Valecillo E; Aroca G; Aza G; González M
    Am J Ther; 2007; 14(2):140-6. PubMed ID: 17414581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perindopril plus nifedipine versus perindopril plus hydrochlorothiazide in mild to severe hypertension: a double-blind multicentre study. The Multicentre Study Group on Treatment Association with Perindopril.
    Letellier P; Overlack A; Agnes E; Desche P
    J Hum Hypertens; 1994 Feb; 8(2):145-9. PubMed ID: 8207741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nifedipine GITS and hydrochlorothiazide in essential hypertension.
    Jueng C; Halperin AK; Hashimoto F; Callender K
    J Clin Hypertens; 1987 Dec; 3(4):695-703. PubMed ID: 3330992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive properties of tiapamil (RO 11-1781)--a new calcium antagonist--in patients with mild and moderate essential hypertension.
    Velasco M; Morillo J; Urbina A; Kögler P; Leishman B; Pasquier M; Hernändez-Pieretti O
    Int J Clin Pharmacol Res; 1987; 7(6):443-54. PubMed ID: 3440635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the anti-ischemia effect of nisoldipine and verapamil. Double-blind randomized cross-over and placebo-controlled acute and long-term study].
    Brügmann U; Blasini R; Rudolph W
    Herz; 1984 Aug; 9(4):244-52. PubMed ID: 6434387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.